Descripción del título
Antiviral Drug Discovery an...
This book summarizes state-of-the-art antiviral drug design and discovery approaches starting from natural products to de novo design, and provides a timely update on recently approved antiviral drugs and compounds in advanced clinical development. Special attention is paid to viral infections with a high impact on the world population or highly relevant from the public health perspective (HIV, hepatitis C, influenza virus, etc.). In these chapters, limitations associated with adverse effects and emergence of drug resistance are discussed in detail. In addition to classical antiviral strategies, chapters will be dedicated to discuss the non-classical drug development strategies to block viral infection, for instance, allosteric inhibitors, covalent antiviral agents, or antiviral compounds targeting proteinâprotein interactions. Finally, current prospects for producing broad-spectrum antiviral inhibitors will be also addressed. The book is distinctive in providing the most recent update in the rapidly evolving field of antiviral therapeutics. Authoritative reviews are written by international scientists well known for their contributions in their topics of research, which makes this book suitable for researchers not only within the antiviral research community but also attractive to a broad audience in the drug discovery field. This book covers molecular structures and biochemical mechanisms mediating the antiviral effects, while discussing various ligand design strategies, which include traditional medicinal chemistry, computational chemistry, and chemical biology approaches. The book provides a comprehensive review of antiviral drug discovery and development approaches, particularly focusing on current innovations and future trends.
Monografía
monografia Rebiun28818883 https://catalogo.rebiun.org/rebiun/record/Rebiun28818883 DE-He213 cr nn 008mamaa 210723s2021 si | s |||| 0|eng d 9789811602672 978-981-16-0267-2 10.1007/978-981-16-0267-2 doi UPNA0538589 UEM 360962 UPVA 997818423103706 UAM 991008097385604211 UCAR 991008232660004213 CBUC 991010501719406709 UR0504403 CBUC 991012574832406708 UR MMG bicssc MED071000 bisacsh MKG thema 615 23 Antiviral Drug Discovery and Development electronic resource] edited by Xinyong Liu, Peng Zhan, Luis Menéndez-Arias, Vasanthanathan Poongavanam. 1st ed. 2021 Singapore Springer Singapore Imprint: Springer 2021. Singapore Singapore Springer Singapore Imprint: Springer XI, 357 p. 142 illus., 64 illus. in color. online resource. XI, 357 p. 142 illus., 64 illus. in color. Text txt rdacontent computer c rdamedia online resource cr rdacarrier text file PDF rda Advances in Experimental Medicine and Biology 0065-2598 1322 1 Antiviral Drugs Against Herpesviruses -- 2 An Update on Antiretroviral Therapy -- 3 Structural Insights to Human Immunodeficiency Virus (HIV-1) Targets and their Inhibition -- 4 LEDGINs, Inhibitors of the Interaction between HIV-1 Integrase and LEDGF/p75, are Potent Antivirals with a Potential to Cure HIV Infection -- 5 Moving Fast Towards Hepatitis B Virus Elimination -- 6 Discovery and Development of Antiviral Therapies for Chronic Hepatitis C Virus Infection -- 7 Phytoconstituents as Lead Compounds for Anti-dengue Drug Discovery -- 8 Anti-influenza Drug Discovery and Development: Targeting the Virus and its Host by all -- 9 Search, Identification and Design of Effective Antiviral Drugs against Pandemic Human Coronaviruses -- 10 Peptide Based Antiviral Drugs -- 11 Covalent Antiviral Agents -- 12 Safe-in-Man Broad Spectrum Antiviral Agents -- 13 Exploiting Ubiquitin ligases for Induced Target Degradation as an Antiviral Strategy. . This book summarizes state-of-the-art antiviral drug design and discovery approaches starting from natural products to de novo design, and provides a timely update on recently approved antiviral drugs and compounds in advanced clinical development. Special attention is paid to viral infections with a high impact on the world population or highly relevant from the public health perspective (HIV, hepatitis C, influenza virus, etc.). In these chapters, limitations associated with adverse effects and emergence of drug resistance are discussed in detail. In addition to classical antiviral strategies, chapters will be dedicated to discuss the non-classical drug development strategies to block viral infection, for instance, allosteric inhibitors, covalent antiviral agents, or antiviral compounds targeting proteinâprotein interactions. Finally, current prospects for producing broad-spectrum antiviral inhibitors will be also addressed. The book is distinctive in providing the most recent update in the rapidly evolving field of antiviral therapeutics. Authoritative reviews are written by international scientists well known for their contributions in their topics of research, which makes this book suitable for researchers not only within the antiviral research community but also attractive to a broad audience in the drug discovery field. This book covers molecular structures and biochemical mechanisms mediating the antiviral effects, while discussing various ligand design strategies, which include traditional medicinal chemistry, computational chemistry, and chemical biology approaches. The book provides a comprehensive review of antiviral drug discovery and development approaches, particularly focusing on current innovations and future trends. Pharmacology. Pharmacy. Biotechnology. Pharmacology/Toxicology. Pharmacy. Biotechnology. Liu, Xinyong. editor. edt. http://id.loc.gov/vocabulary/relators/edt Zhan, Peng. editor. edt. http://id.loc.gov/vocabulary/relators/edt Menéndez-Arias, Luis. editor. edt. http://id.loc.gov/vocabulary/relators/edt Poongavanam, Vasanthanathan. editor. edt. http://id.loc.gov/vocabulary/relators/edt SpringerLink (Online service) Springer Nature eBook Springer Nature eBook Printed edition 9789811602665 Printed edition 9789811602689 Printed edition 9789811602696 Advances in Experimental Medicine and Biology 0065-2598 1322.